Ulocuplumab (INN; development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.Statement On A Nonproprietary Name Adopted By The USAN Council - Ulocuplumab, American Medical Association. Ulocuplumab targets CXCR4.
This drug was developed by Bristol-Myers Squibb.
References